Alnylam Pharmaceuticals, Inc. (ALNY) trades at a trailing P/E of 137.3, forward P/E of 50.8. Trailing earnings yield is 0.73%, forward earnings yield 1.97%. PEG 0.27 (Peter Lynch undervalued ≤1.0). Graham Number is $17.85.
Criteria proven by this page:
Overall SharesGrow Score: 60/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -7.8 | -0.20 | 3.48 | 67.96 | - |
| 2017 | -23.4 | -1.78 | 6.51 | 127.96 | - |
| 2018 | -9.6 | -0.24 | 5.63 | 97.91 | - |
| 2019 | -14.2 | -1.99 | 8.75 | 57.26 | - |
| 2020 | -17.4 | 2.17 | 14.71 | 30.32 | - |
| 2021 | -23.6 | 6.76 | 34.15 | 23.79 | - |
| 2022 | -25.6 | -0.88 | -182.78 | 27.88 | - |
| 2023 | -54.3 | 0.87 | -108.36 | 13.08 | - |
| 2024 | -108.0 | 2.84 | 447.73 | 13.36 | - |
| 2025 | 166.0 | -0.79 | 66.01 | 14.03 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-4.79 | $47.16M | $-410.11M | -869.6% |
| 2017 | $-5.42 | $89.91M | $-490.87M | -545.9% |
| 2018 | $-7.57 | $74.91M | $-761.5M | -1016.6% |
| 2019 | $-8.11 | $219.75M | $-886.12M | -403.2% |
| 2020 | $-7.46 | $492.85M | $-858.28M | -174.1% |
| 2021 | $-7.20 | $844.29M | $-852.82M | -101% |
| 2022 | $-9.30 | $1.04B | $-1.13B | -109% |
| 2023 | $-3.52 | $1.83B | $-440.24M | -24.1% |
| 2024 | $-2.16 | $2.25B | $-278.16M | -12.4% |
| 2025 | $2.33 | $3.71B | $313.75M | 8.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $6.55 | $5.64 – $7.43 | $5.56B | $5.17B – $6.11B | 15 |
| 2027 | $10.51 | $8.31 – $13.30 | $7.35B | $6.67B – $9.03B | 13 |
| 2028 | $13.52 | $9.80 – $20.43 | $8.76B | $8.67B – $8.85B | 16 |
| 2029 | $16.09 | $14.17 – $19.82 | $9.98B | $9.06B – $11.76B | 14 |
| 2030 | $19.21 | $16.92 – $23.66 | $11.36B | $10.31B – $13.38B | 14 |
